Persistent URL of this record https://hdl.handle.net/1887/102620
In Collections
This item can be found in the following collections:
![Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
- All authors
- Reichardt, P.; Demetri, G.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; Rutkowski, P.; Hohenberger, P.; Gelderblom, H.; Leahy, M.G.; Mehren, M. von; Schoffski, P.; Blackstein, M.E.; Cesne, A. le; Badalamenti, G.; Xu, J.; Nishida, T.; Kuss, I.; Casali, P.G.
- Date
- 2013-10-31
- Journal
- Onkologie
- Volume
- 36
- Pages
- 179 - 180